PTC Therapeutics Gets $1m Grant Award From NIH

PTC Therapeutics (PTC) has received $1m challenge grant award from the National Heart, Lung, and Blood Institute (NHLBI) as part of the National Institutes of Health (NIH). The two-year grant is expected to support an ongoing Phase 2a clinical trial of Ataluren in hemophilia A and B due to a nonsense mutation.

Reportedly, PTC has initiated of the Phase 2a clinical trial of Ataluren, an oral investigational new drug, in adult male patients with nonsense mutation hemophilia A and nonsense mutation hemophilia B.

Stuart Peltz, president and CEO of PTC, said: “We are honored to receive this grant from the NIH. A majority of the grants were awarded to academic institutions, non-profits and hospitals and we are proud to be one of the few corporations to receive funding. This grant supports our continued commitment to developing innovative therapies for patients with serious and life threatening conditions.”